Reuters Market Eye - Shares of Indian pharmaceutical companies perceived as defensive gain on risk aversion after overseas investors sold 2.67 billion rupees worth of Indian shares on Friday, extending their selling streak to a seventh day, provisional exchange data shows, dealers say.
"Stable cash flows and lower volatility of Indian pharma stocks are leading to some flows in the sector ahead of key events like Yellen's speech and inflation data," a dealer said.
Sun Pharmaceutical Industries Ltd gains 1.8 percent, Dr.Reddy's Laboratories Ltd is up 1.9 percent and Cipla Ltd is higher 1.2 percent.
Caution is also seen ahead of consumer price inflation and industrial output data due later in the week.
(Reporting by Abhishek Vishnoi)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app